A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.

ABSTRACT:

Objective

The aim of this study was to examine the tolerability and efficacy of combination bevacizumab rucaparib therapy in patients with recurrent cervical or endometrial cancer.

Patients & methods

Thirty-three patients with recurrent cervical or endometrial cancer were enrolled. Patients were required to have tumor progression after first line treatment for metastatic, or recurrent disease. Rucaparib was given at 600 mg BID twice daily for each 21-day cycle. Bevacizumab was given at 15 mg/kg on day 1 of each 21-day cycle. The primary endpoint was efficacy as determined by objective response rate or 6-month progression free survival.

Results

Of the 33 patients enrolled, 28 were evaluable. Patients with endometrial cancer had a response rate of 17% while patients wit

SUBMITTER: Jackson CG 

PROVIDER: S-EPMC10428664 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature